Opportunity ID: 329236

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-20-305
Funding Opportunity Title: Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2021, 2022, and 2023 (P50 Clinical Trial Required)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.121 — Oral Diseases and Disorders Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 3
Posted Date: Sep 28, 2020
Last Updated Date: Sep 25, 2023
Original Closing Date for Applications: Jan 07, 2024
Current Closing Date for Applications: Sep 26, 2023
Archive Date: Oct 26, 2023
Estimated Total Program Funding:
Award Ceiling: $1,400,000
Award Floor:

Eligibility

Eligible Applicants: Public and State controlled institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Native American tribal governments (Federally recognized)
Private institutions of higher education
Independent school districts
State governments
Special district governments
Public housing authorities/Indian housing authorities
For profit organizations other than small businesses
City or township governments
County governments
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Native American tribal organizations (other than Federally recognized tribal governments)
Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Additional Information

Agency Name: National Institutes of Health
Description:

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPORE). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. For the purpose of this FOA, a group of highly related cancers are those that are derived from the same organ system, such as gastrointestinal, neuroendocrine, head and neck, and other cancers. Other programmatically appropriate groups of cancers may include those centered around a common biological mechanism critical for promoting tumorigenesis and/or cancer progression in organ sites that belong to different organ systems. For example, a SPORE may focus on cancers caused by the same infectious agent or cancers promoted and sustained by dysregulation of a common signaling pathway. In addition, a SPORE may focus on cross-cutting themes such as pediatric cancers or cancer health disparities. The research supported through this program must be translational and must stem from research on human biology using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant.

Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-20-305.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster

FBOWebmaster@OD.NIH.GOV
Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date
Changing expiration per issuance of PAR-23-284 Sep 25, 2023
expired and re-issued Sep 28, 2020
Sep 28, 2020

DISPLAYING: Synopsis 3

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-20-305
Funding Opportunity Title: Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2021, 2022, and 2023 (P50 Clinical Trial Required)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.121 — Oral Diseases and Disorders Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 3
Posted Date: Sep 28, 2020
Last Updated Date: Sep 25, 2023
Original Closing Date for Applications: Jan 07, 2024
Current Closing Date for Applications: Sep 26, 2023
Archive Date: Oct 26, 2023
Estimated Total Program Funding:
Award Ceiling: $1,400,000
Award Floor:

Eligibility

Eligible Applicants: Public and State controlled institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Native American tribal governments (Federally recognized)
Private institutions of higher education
Independent school districts
State governments
Special district governments
Public housing authorities/Indian housing authorities
For profit organizations other than small businesses
City or township governments
County governments
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Native American tribal organizations (other than Federally recognized tribal governments)
Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Additional Information

Agency Name: National Institutes of Health
Description:

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPORE). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. For the purpose of this FOA, a group of highly related cancers are those that are derived from the same organ system, such as gastrointestinal, neuroendocrine, head and neck, and other cancers. Other programmatically appropriate groups of cancers may include those centered around a common biological mechanism critical for promoting tumorigenesis and/or cancer progression in organ sites that belong to different organ systems. For example, a SPORE may focus on cancers caused by the same infectious agent or cancers promoted and sustained by dysregulation of a common signaling pathway. In addition, a SPORE may focus on cross-cutting themes such as pediatric cancers or cancer health disparities. The research supported through this program must be translational and must stem from research on human biology using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant.

Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-20-305.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster

FBOWebmaster@OD.NIH.GOV
Email:FBOWebmaster@OD.NIH.GOV

DISPLAYING: Synopsis 2

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-20-305
Funding Opportunity Title: Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2021, 2022, and 2023 (P50 Clinical Trial Required)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.121 — Oral Diseases and Disorders Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 2
Posted Date: Sep 28, 2020
Last Updated Date: Sep 22, 2023
Original Closing Date for Applications:
Current Closing Date for Applications: Sep 22, 2023
Archive Date: Oct 22, 2023
Estimated Total Program Funding:
Award Ceiling: $1,400,000
Award Floor:

Eligibility

Eligible Applicants: City or township governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
Public and State controlled institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Special district governments
For profit organizations other than small businesses
Independent school districts
State governments
County governments
Public housing authorities/Indian housing authorities
Private institutions of higher education
Native American tribal governments (Federally recognized)
Native American tribal organizations (other than Federally recognized tribal governments)
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Additional Information

Agency Name: National Institutes of Health
Description:

Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPORE). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. For the purpose of this FOA, a group of highly related cancers are those that are derived from the same organ system, such as gastrointestinal, neuroendocrine, head and neck, and other cancers. Other programmatically appropriate groups of cancers may include those centered around a common biological mechanism critical for promoting tumorigenesis and/or cancer progression in organ sites that belong to different organ systems. For example, a SPORE may focus on cancers caused by the same infectious agent or cancers promoted and sustained by dysregulation of a common signaling pathway. In addition, a SPORE may focus on cross-cutting themes such as pediatric cancers or cancer health disparities. The research supported through this program must be translational and must stem from research on human biology using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant.

Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-20-305.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster

FBOWebmaster@OD.NIH.GOV
Email:FBOWebmaster@OD.NIH.GOV

DISPLAYING: Synopsis 1

General Information

Document Type: Grants Notice
Funding Opportunity Number: PAR-20-305
Funding Opportunity Title: Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2021, 2022, and 2023 (P50 Clinical Trial Required)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Education
Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.121 — Oral Diseases and Disorders Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Sep 28, 2020
Last Updated Date: Sep 28, 2020
Original Closing Date for Applications:
Current Closing Date for Applications: Jan 07, 2024
Archive Date: Feb 12, 2024
Estimated Total Program Funding:
Award Ceiling: $1,400,000
Award Floor:

Eligibility

Eligible Applicants: City or township governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
Public and State controlled institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Special district governments
For profit organizations other than small businesses
Independent school districts
State governments
County governments
Public housing authorities/Indian housing authorities
Private institutions of higher education
Native American tribal governments (Federally recognized)
Native American tribal organizations (other than Federally recognized tribal governments)
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Additional Information

Agency Name: National Institutes of Health
Description: Through this funding opportunity announcement (FOA), the National Cancer Institute (NCI) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPORE). The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. For the purpose of this FOA, a group of highly related cancers are those that are derived from the same organ system, such as gastrointestinal, neuroendocrine, head and neck, and other cancers. Other programmatically appropriate groups of cancers may include those centered around a common biological mechanism critical for promoting tumorigenesis and/or cancer progression in organ sites that belong to different organ systems. For example, a SPORE may focus on cancers caused by the same infectious agent or cancers promoted and sustained by dysregulation of a common signaling pathway. In addition, a SPORE may focus on cross-cutting themes such as pediatric cancers or cancer health disparities. The research supported through this program must be translational and must stem from research on human biology using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant.
Link to Additional Information: http://grants.nih.gov/grants/guide/pa-files/PAR-20-305.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
Email:FBOWebmaster@OD.NIH.GOV

Folder 329236 Full Announcement-PAR-20-305 -> PAR-20-305-Full-Announcement.pdf

Packages

Agency Contact Information: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
Email: FBOWebmaster@OD.NIH.GOV
Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-F Use for due dates on or before January 24, 2022 PKG00263604 Dec 25, 2020 Jan 24, 2022 View
FORMS-G Use for due dates on or before January 24, 2023 PKG00269950 Oct 29, 2021 Jan 24, 2023 View
FORMS-H Use for due dates on or after January 25, 2023 PKG00277483 Oct 27, 2022 Sep 26, 2023 View

Package 1

Mandatory forms

329236 RR_SF424_2_0-2.0.pdf

329236 PHS398_CoverPageSupplement_5_0-5.0.pdf

329236 RR_OtherProjectInfo_1_4-1.4.pdf

329236 PerformanceSite_2_0-2.0.pdf

329236 RR_KeyPersonExpanded_2_0-2.0.pdf

329236 PHS398_ResearchPlan_4_0-4.0.pdf

329236 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf

Optional forms

329236 PHS_Additional_IndirectCosts-1.0.pdf

329236 PHS_AssignmentRequestForm_3_0-3.0.pdf

Package 2

Mandatory forms

329236 RR_SF424_5_0-5.0.pdf

329236 PHS398_CoverPageSupplement_5_0-5.0.pdf

329236 RR_OtherProjectInfo_1_4-1.4.pdf

329236 PerformanceSite_4_0-4.0.pdf

329236 RR_KeyPersonExpanded_4_0-4.0.pdf

329236 PHS398_ResearchPlan_4_0-4.0.pdf

329236 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

329236 PHS_Additional_IndirectCosts_2_0-2.0.pdf

329236 PHS_AssignmentRequestForm_3_0-3.0.pdf

Package 3

Mandatory forms

329236 RR_SF424_5_0-5.0.pdf

329236 PHS398_CoverPageSupplement_5_0-5.0.pdf

329236 RR_OtherProjectInfo_1_4-1.4.pdf

329236 PerformanceSite_4_0-4.0.pdf

329236 RR_KeyPersonExpanded_4_0-4.0.pdf

329236 PHS398_ResearchPlan_5_0-5.0.pdf

329236 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf

Optional forms

329236 PHS_Additional_IndirectCosts_2_0-2.0.pdf

329236 PHS_AssignmentRequestForm_3_0-3.0.pdf

2025-07-10T15:54:17-05:00

Share This Post, Choose Your Platform!

About the Author: